A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

NCT03752294 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Investigator left institution

Conditions

Mild Cognitive Impairment
Mild Alzheimer's Disease

Interventions

DRUG: Dabigatran
DRUG: Placebo - Cap

Sponsor

University of Rhode Island

Collaborators

[object Object]
[object Object]